BiotechTube

Combination of bempedoic acid and ezetimibe

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Hypercholesterolaemia

Conditions

Primary Hypercholesterolaemia, Mixed Dyslipidemia

Trial Timeline

Jan 30, 2026 → Mar 1, 2029

NCT ID
NCT07206472

About Combination of bempedoic acid and ezetimibe

Combination of bempedoic acid and ezetimibe is a pre-clinical stage product being developed by Daiichi Sankyo for Primary Hypercholesterolaemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07206472. Target conditions include Primary Hypercholesterolaemia, Mixed Dyslipidemia.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT07206472Pre-clinicalRecruiting

Competing Products

20 competing products in Primary Hypercholesterolaemia

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
22
azenosertibZentalis PharmaceuticalsPhase 2
44
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
77
REN001OnKure TherapeuticsPhase 1
25
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
44
REN001OnKure TherapeuticsPhase 2/3
57
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
44
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
52
Rituximab, lenalidomideCelltrionPhase 2
52
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPre-clinical
23
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
23
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
DS-8201a + T-DM1Daiichi SankyoPhase 3
77
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
23
Roxadustat + PlaceboAstellas PharmaPhase 3
77
Enzalutamide + ExemestaneAstellas PharmaPhase 2
52
Bocidelpar + PlaceboAstellas PharmaPhase 2
52
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
52
Brinzolamide ophthalmic suspension + Azopt®Sun PharmaceuticalPhase 3
77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85